» Articles » PMID: 31673296

Hyperhomocysteinemia is an Independent Risk Factor of Atherosclerosis in Patients with Metabolic Syndrome

Overview
Publisher Biomed Central
Specialty Endocrinology
Date 2019 Nov 2
PMID 31673296
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Metabolic syndrome (MetS) is a clinical condition potentially promoting the development of atherosclerotic disease. To date, the clinical impact of elevated serum homocysteine (Hcy) levels in MetS is still under discussion. The aim of this cross sectional study was to evaluate the relationship between MetS and hyperhomocysteinemia and the potential role of Hcy in the pathogenesis of atherosclerotic complications of MetS.

Methods: We recruited 300 outpatients with MetS. All patients underwent a medical history collection, physical examination, blood sampling and carotid ultrasound echo-color Doppler. According to Hcy levels, MetS patients were divided into two groups: "normal" (< 10.7 μmol/l; n = 140, group 1) and "high" Hcy (≥ 10.7 μmol/l; n = 160, group 2). Comparisons between groups were made by Student's t-test or Chi-square test. The effects of potential covariates on group differences were evaluated by general linear models. The relationships between continuous variables were assessed by simple or multiple correlation and by linear regression. Multiple regression models were built to evaluate the effects of Hcy, together with other potential risk factors, on carotid atherosclerosis.

Results: Patients with high Hcy were predominantly male and slightly older than group 1 patients. Smokers and non-smokers exhibited similar Hcy levels, nor was a statistical relationship between pack-years and Hcy observed. Group 2 showed lower levels of folic acid, vitamin D, high density lipoprotein (HDL)-cholesterol and glomerular filtration rate (e-GFR) than group 1, but higher levels of C-peptide, uric acid and triglycerides. In all patients, Hcy was positively correlated with C-peptide and uric acid and negatively with folic acid and e-GFR. Intima-media thickness (IMT) and carotid stenosis degree were significantly higher in patients with high Hcy and a positive relationship between Hcy and both IMT and carotid stenosis was detected in all patients. Finally, Hcy atherogenic effects were independent of other well-known atherosclerosis risk factors.

Conclusions: Our results highlight a link between MetS and hyperhomocysteinemia and a direct effect of Hcy on atherogenic process during MetS. Early correction of folic acid levels may contribute to prevent cardiovascular complications in MetS patients.

Citing Articles

Integration of epigenomic and transcriptomic profiling uncovers EZH2 target genes linked to cysteine metabolism in hepatocellular carcinoma.

Lee J, You C, Kwon G, Noh J, Lee K, Kim K Cell Death Dis. 2024; 15(11):801.

PMID: 39516467 PMC: 11549485. DOI: 10.1038/s41419-024-07198-0.


Atherogenic Effect of Homocysteine, a Biomarker of Inflammation and Its Treatment.

Prasad K Int J Angiol. 2024; 33(4):262-270.

PMID: 39502352 PMC: 11534477. DOI: 10.1055/s-0044-1788280.


Association between homocysteine levels and hyperlipidemia prevalence as well as all-cause mortality of hyperlipidemia patients in the US population: results from NHANES database.

Wei J, Yang Q, Wang X, He X, Zhu W, Lin L Front Cardiovasc Med. 2024; 11:1419579.

PMID: 39119183 PMC: 11306012. DOI: 10.3389/fcvm.2024.1419579.


Nicotinamide N-methyltransferase (NNMT): a novel therapeutic target for metabolic syndrome.

Sun W, Zhu X, Li J, Mei Y, Li W, Li J Front Pharmacol. 2024; 15:1410479.

PMID: 38919254 PMC: 11196770. DOI: 10.3389/fphar.2024.1410479.


A Proactive Intervention Study in Metabolic Syndrome High-Risk Populations Using Phenome-Based Actionable P4 Medicine Strategy.

Huang Q, Hu Z, Zheng Q, Mao X, Lv W, Wu F Phenomics. 2024; 4(2):91-108.

PMID: 38884061 PMC: 11169348. DOI: 10.1007/s43657-023-00115-z.


References
1.
Tak Y, Jeong D, Kim Y, Lee S, Lee J, Song S . Hyperhomocysteinaemia as a potential marker of early renal function decline in middle-aged Asian people without chronic kidney disease. Int Urol Nephrol. 2016; 48(2):239-48. DOI: 10.1007/s11255-015-1180-0. View

2.
Katsiki N, Mikhailidis D . Emerging Vascular Risk Factors in Women: Any Differences from Men?. Curr Med Chem. 2015; 22(31):3565-79. DOI: 10.2174/0929867322666150904110053. View

3.
Vaughn J, Bailey L, Shelnutt K, Dunwoody K, Maneval D, Davis S . Methionine synthase reductase 66A->G polymorphism is associated with increased plasma homocysteine concentration when combined with the homozygous methylenetetrahydrofolate reductase 677C->T variant. J Nutr. 2004; 134(11):2985-90. DOI: 10.1093/jn/134.11.2985. View

4.
Kundi H, Kiziltunc E, Ates I, Cetin M, Barca A, Ozkayar N . Association between plasma homocysteine levels and end-organ damage in newly diagnosed type 2 diabetes mellitus patients. Endocr Res. 2016; 42(1):36-41. DOI: 10.3109/07435800.2016.1171235. View

5.
Hannibal L, Blom H . Homocysteine and disease: Causal associations or epiphenomenons?. Mol Aspects Med. 2016; 53:36-42. DOI: 10.1016/j.mam.2016.11.003. View